Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
-136.45%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$6.74M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$7.07M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$6.60M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.60M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | 80.62% | 90.31% | -419.28% | -4158.68% |
| KALA BIO, Inc. (KALA)vs › | $7.04M | 0.00% | 0.00% | 8.55% | 24.65% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | 0.00% | 0.00% | 4.26% | 4.26% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.15M | 69.76% | 72.87% | 54.39% | 49.20% |
| Biomerica, Inc. (BMRA)vs › | $6.61M | 8.09% | 8.76% | 9.29% | 9.67% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclarion, Inc. (ACON)vs › | $6.60M | -291.27% | -237.54% | -120.88% | -89.07% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 95.07% |
| 2022-09-30 | -138.34% |
| 2022-06-30 | -173.13% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | -439.05% |
| 2021-09-30 | 547.57% |
| 2021-06-30 | -13625.32% |
| 2021-03-31 | -929.29% |
| 2020-12-31 | -6951.43% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | -44.58% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | -2566.77% |
| 2019-09-30 | -705.50% |
| 2019-06-30 | -691.01% |
| 2019-03-31 | -13480.00% |
| 2018-12-31 | -50033.33% |
| 2018-09-30 | -6919.30% |
| 2018-06-30 | -20084.21% |
| 2018-03-31 | -8997.22% |
| 2017-12-31 | -51.31% |
| 2017-09-30 | -24.99% |
| 2017-06-30 | -22.49% |
| 2017-04-01 | -43.42% |
| 2016-12-31 | -672.46% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | -1609.83% |
| 2016-03-31 | -1609.83% |
